Related Experiment Video
Updated: Jul 22, 2026

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty
Published on: October 6, 2016
Physical Activity Limitations In Children With Severe Haemophilia A. Does Emicizumab Make A Difference?
Ahmed Sobhi Hassan1, Laila Metwally Sherief2, Mona Hamdy3
1Department of Pediatrics, Kafrelsheikh University,Egypt.
Insights
Emicizumab prophylaxis significantly improved physical activity in children with severe haemophilia A. This treatment enhanced the quality of life for young patients managing this rare bleeding disorder.
Area of Science:
- Paediatric Haematology
- Clinical Paediatrics
- Pharmacology
Background:
- Severe haemophilia A impacts children's physical activity and quality of life.
- Current treatments aim to prevent bleeding episodes and improve patient outcomes.
- Emicizumab offers a novel prophylactic option for severe haemophilia A.
Purpose of the Study:
- To evaluate the impact of emicizumab prophylaxis on physical activity levels in children with severe haemophilia A.
- To assess changes in physical activity using the Paediatric Haemophilia Activities List.
- To determine the efficacy of emicizumab in improving daily functioning for these patients.
Main Methods:
- Prospective cohort study conducted between October 2021 and April 2022.
- Involved 29 children (aged 4-18 years) with severe haemophilia A receiving emicizumab prophylaxis.
- Physical activity assessed at baseline and after six months using the Paediatric Haemophilia Activities List.
Main Results:
- A significant increase in the Paediatric Haemophilia Activities List sum score was observed post-intervention (median 59.54 to 84, p<0.001).
- The study included 29 boys, with a mean age of 8.7 years.
- 58.62% of patients were negative for inhibitors.
Conclusions:
- Emicizumab prophylaxis demonstrated a significant improvement in physical activity levels for children with severe haemophilia A.
- This suggests emicizumab can positively impact the functional capacity and well-being of young patients.
- Further research can explore long-term effects and broader quality-of-life improvements.
Objectives:
To assess the effect of emicizumab on physical activity in children with severe haemophilia A.
Methods:
The prospective cohortstudy was conducted from October 2021 to April 2022 at the Paediatric Department of Kafrelsheikh University Hospital, Egypt, in collaboration with the Haematology out-patient clinic of the Paediatric Department, Zagazig University, Egypt, and the Paediatric Department of Cairo University Hospital, Egypt, and comprised children aged 4-18 years with severe haemophilia A who received emicizumab prophylaxis. Paediatric Haemophilia Activities List was used to assess physical activity at baseline and aftersix months of regular emicizumab prophylaxis. Data was analysed using SPSS 26.
Results:
There were 29 children, all (100%) boys, with mean age 8.7±3.51 years(range 4-15 years. Of them, 17(58.62%) patients were negative for inhibitors. Median Paediatric Haemophilia Activities Listsum score was 59.54 (interquartile range: 50.15-62.05) at baseline which moved up to 84 (interquartile range: 79.05-86.35) post-intervention (p<0.001).
Conclusions:
Emicizumab prophylaxis improved the level of physical activity in children with severe haemophilia A.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Exercise and Cardiac Output
Sustained exercise increases the muscles' oxygen demand, which can be met...

